Shire (LON:SHP) has been assigned a consensus recommendation of “Buy” from the twenty-one analysts that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is GBX 4,708.82 ($66.10).
A number of research analysts recently commented on SHP shares. Barclays started coverage on Shire in a research note on Thursday, February 1st. They issued an “equal weight” rating for the company. Citigroup reaffirmed a “buy” rating and issued a GBX 5,500 ($77.20) price target on shares of Shire in a research note on Friday, December 8th. Shore Capital reaffirmed a “buy” rating on shares of Shire in a research note on Monday, January 15th. Deutsche Bank reaffirmed a “buy” rating on shares of Shire in a research note on Monday, December 11th. Finally, Liberum Capital downgraded Shire to a “hold” rating and dropped their price target for the company from GBX 4,200 ($58.96) to GBX 4,100 ($57.55) in a research note on Wednesday, December 20th.
Shares of Shire stock traded up GBX 1.50 ($0.02) during trading on Friday, reaching GBX 3,708.50 ($52.06). The company’s stock had a trading volume of 3,081,841 shares, compared to its average volume of 3,140,000. Shire has a 52 week low of GBX 2,940.50 ($41.28) and a 52 week high of GBX 5,021 ($70.48).
WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3335690/brokerages-set-shire-shp-pt-at-4708-82.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.